Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00869232 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary and study completion dates: Oct 2015 to Oct 2016v9
NotablePrimary and study completion dates: Oct 2013 to Oct 2015v8
MinorRe-verified, no change to tracked fieldsv7
NotablePrimary and study completion dates: Oct 2012 to Oct 2013v6
MinorRe-verified, no change to tracked fieldsv5
NotablePrimary endpoint revised
Secondary endpoint revised
v4
NotablePrimary completion date: Oct 2010 to Oct 2012
Study completion date: Oct 2011 to Oct 2012
v3
MinorStudy Identification, Study Statusv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have lived longer and had better responses to treatment) when compared to individuals treated with standard chemotherapy.
Past studies conducted at the MIRT and at other institutions have shown that participants with high-risk features by gene array studies tend to have shorter remissions (disappearance of signs and symptoms of myeloma) and do not survive as long as participants with low-risk myeloma. Researchers at MIRT think that one reason for this is that the myeloma cells re-grow in the time when participants are not receiving treatment because they are recovering from high-dose chemotherapy. In this study, participants will receive several chemotherapy drugs previously shown to be effective in myeloma, but in lower doses and in shorter cycles. It is hoped that by giving the drugs in this way, myeloma cells will not have time to re-grow between cycles, therefore resulting in longer remissions. This study is being done in an attempt to improve the remission rate and the survival time for participants with high-risk myeloma.